Systemic Lupus Erythematosus: An Overview of the Disease Pathology and Its Management.

Autor:	Ali A; Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, PAK., Sayyed Z; Pediatrics, Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental College, Bahawalpur, PAK., Ameer MA; Department of Internal Medicine, Lahore Medical and Dental College, Lahore, PAK., Arif AW; Medicine, Shaikh Zayed Hospital, Lahore, PAK., Kiran F; Internal Medicine, Basic Health Unit Larhi, Gambat, PAK., Iftikhar A; Internal Medicine, Nishtar University, Multan, Multan, PAK., Iftikhar W; Internal Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, PAK., Ahmad MQ; Hematology/Oncology, University of Arizona Cancer Center, Tucson, USA., Malik MB; Internal Medicine, Shifa College of Medicine, Islamabad, PAK., Kumar V; Internal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK., Dass A; Internal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK., Sami SA; Internal Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, PAK., Sapna F; Internal Medicine, Burhani Hospital, Karachi, PAK., Waqas N; Surgery, Shaikh Khalifa Bin Zayed Al Nahyan Medical & Dental College, Broken Bow, PAK.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2018 Sep 11; Vol. 10 (9), pp. e3288. Date of Electronic Publication: 2018 Sep 11.
DOI:	10.7759/cureus.3288
Abstrakt:	Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with varied natural history and multisystemic involvement. The pathogenesis is multifactorial and complex precipitating the formation of autoantibodies. One of the main factors in SLE is the interaction between environmental triggers and genetic factors. Genome-wide association study technology has led to the identification of more than 80 loci which produce key proteins that lead to small pathophysiological changes and are associated with SLE. There has been an improvement in the management of the disease with newly standardized scores that have been validated in assessing disease activity and quality of life, and have helped in clinical care as well as research. The last five decades have seen a marked improvement in the prognosis of SLE, thanks to better general care and the development of newer immunosuppressive drugs, more specifically biological agents. Competing Interests: The authors have declared that no competing interests exist.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu